JAZZ Jazz Pharmaceuticals plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1232524 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.5%
TTM net income YoY155.9%
TTM EPS YoY154.9%
Revenue 3-yr CAGR7.5%
Net income 3-yr CAGR37.1%
Margins
Gross margin—
Operating margin9.0%
Net margin4.4%
FCF margin34.4%
EBITDA margin9.8%
Returns
ROE5.1%
ROA1.8%
ROIC (approx.)4.3%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets65.1%
Debt / equity1.33x
Current ratio1.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income8.22x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.27B | $4.07B |
| R&D expense | $782.74M | $884.00M |
| SG&A expense | $1.81B | $1.39B |
| Operating income | -$430.24M | $716.63M |
| Pretax income | -$627.86M | $470.35M |
| Income tax | -$272.44M | -$91.43M |
| Net income | -$356.15M | $560.12M |
| EBITDA | -$388.64M | $749.43M |
| EPS (basic) | -5.84 | 9.06 |
| EPS (diluted) | -5.84 | 8.65 |
| Weighted avg. shares (diluted) | 60.98M | 66.01M |
| Balance sheet | ||
| Cash & equivalents | $1.39B | $2.41B |
| Receivables | $830.70M | $716.76M |
| Inventory | $417.00M | $480.44M |
| Current assets | $4.17B | $4.63B |
| PP&E, net | $199.90M | $173.41M |
| Goodwill | $1.83B | $1.72B |
| Intangibles | $4.43B | $4.76B |
| Total assets | $11.66B | $12.01B |
| Current liabilities | $2.24B | $1.04B |
| Short-term debt | $1.03B | $31.00M |
| Long-term debt | $4.33B | $6.08B |
| Total debt | $5.36B | $6.11B |
| Total liabilities | $7.34B | $7.92B |
| Shareholders' equity | $4.32B | $4.09B |
| Net debt | $3.97B | $3.70B |
| Shares outstanding | 61.44M | 60.63M |
| Cash flow statement | ||
| Operating cash flow | $1.36B | $1.40B |
| Capital expenditure | $58.75M | $38.07M |
| Free cash flow | $1.30B | $1.36B |
| Investing cash flow | -$1.51B | -$508.19M |
| Financing cash flow | -$873.38M | $20.52M |
| Depreciation & amortization | $41.60M | $32.80M |
| Stock-based compensation | $291.13M | $248.04M |
| Share buybacks | $125.02M | $311.43M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.